Almost two-thirds of people with depression report two or more traumatic events in childhood as compared to people who don't have depression. And, clinicians are seeing a worldwide increase in depression due to the coronavirus pandemic. This podcast breaks down how Brintellix can improve the quality of life for patients with depression associated with recent or childhood trauma as well as its clinical relevance in increasing cognitive function and reducing anhedonia.
Professor Roger McIntyre is an expert in depression therapy and a doctor whom Thomson Reuters named one of the most influential scientific minds in 2014–2019. Michael Cronquist Christensen is the Global Vortioxetine Medical Lead at Lundbeck.
Key Takeaways:
[:59] The epidemiology of patients with childhood or recent trauma in relation to depression.
[3:45] The role of resilience in relation to patients who have childhood or recent trauma.
[6:04] The unique effects of Brintellix on cognition and anhedonia in trauma patients.
[7:47] Studies show vortioxetine augments antidepressants, reduces relapses, and increases function and quality of life in trauma patients.
[12:54] Commonly encountered scenarios in clinical assessments of patients with a history of trauma.
[15:55] Professor McIntyres' recommended dose of Brintellix for patients with a history of trauma.
Resources:
